Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 5, 1997, Pages 572-577

  Donahue, Stephen K ^a   Flockhart, David A ^a   Abernethy, Darrell R ^a   Ko, Jae Wook ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CIMETIDINE; CYTOCHROME P450 ISOENZYME; ENALAPRIL; METOPROLOL; PHENOBARBITAL; PHENYTOIN; TICLOPIDINE;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; ENZYME INHIBITION; GENOTYPE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTOXICATION; LIVER MICROSOME; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEIZURE; VERTIGO;

ADULT; ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MALE; MIXED FUNCTION OXYGENASES; PHENYTOIN; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 0031430539     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90054-0     Document Type: Article

References (29)

1. Desager JP. Clinical pharmacokinetics of ticlopidine. Clin Pharmacokinet 1994;26:347-55.
2. Knudsen JB, Bastain W, Sefton CM, Allen JG, Dickinson JP. Pharmacokinetics of ticlopidine during chronic oral administration to healthy volunteers and its effects on antipyrine pharmacokinetics. Xenobiotica 1992;22:579-89.
3. Shah J, Teitelbaum P, Molony B, Gabuzda T, Massey I. Single and multiple dose pharmacokinetics of ticlopidine in young and elderly subjects. Br J Clin Pharmacol 1991;32:761-4.
4. Colli A, Buccino G, Cocciolo M, Parravicini R, Elli GM, Scaltrini G. Ticlopidine - theophylline interaction. Clin Pharmacol Ther 1987;41:358-62.
5. Giddal BE, Sorkness CA, McGill KA, Larson R, Levine RR. Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995; 17:33-8.
6. Rindon JP, Bryan G II, Ariz P. Phenytoin toxicity associated with ticlopidine administration [letter]. Arch Intern Med 1996;156:1113.
7. Privitera M, Welty TE. Acute phenytoin toxicity followed by seizure breakthrough from a ticlopidinephenytoin interaction. Arch Neurol 1996;53:1191-2.
8. Riva R, Cerullo A, Albani F, Baruzzi A. Ticlopidine impairs phenytoin clearance; a case report. Neurology 1996;46:1172-73.
9. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
10. Flockhart DA, Buchert E, Harris JW, Clauw DJ, Woosley RL. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome. Clin Pharmacol Ther 1994;56:398-405.
11. Richens A, Dunlop A. Serum phenytoin levels in the management of epilepsy. Lancet 1975;2:247-8.
12. Vozeh S, Muir KT, Sheiner LB, Follath F. Predicting individual phenytoin dosage. J Pharmacokinet Biopharm 1981;9:131-46.
13. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994;54:4026-35.
14. Relling MV, Aoyama T, Gonzalez F, Meyer UA. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990;252:442-7.
15. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
16. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
17. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997;25:853-62.
18. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
19. Flockhart DA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol 1996;16:101-3.
20. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P450 2C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996;24:1401-3.
21. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995;36(suppl 5):S8-13.
22. Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolizing cytochrome P450 isozymes (CYP2C9, CYP2D6, and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996;50:209-15.
23. Levine M, Jones MW, Sheppard I. Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin. Neurology 1985;35:562-5.
24. Paxton JW. Effects of aspirin on salivary and serum phenytoin pharmacokinetics in healthy subjects. Clin Pharmacol Ther 1980;27:170-8.
25. [Anonymous]. Ticlid (ticlopidine). Physician's desk reference. 51st ed. Montvale NJ: Medical Economics; 1997. p. 2317-9.
26. Sellers EM. Plasma protein displacement interactions are rarely of clinical significance. Pharmacology 1979; 18:225-7.
27. Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin. Clin Pharmacokinet 1990;18:37-60.
28. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole; I: inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996;24:414-21.
29. Wienkers LC, Wurden CJ, Storch E, Kunze KL, Rettie AE, Trager WF. Formation of (R)-8-hydroxywarfarin in human liver microsomes: a new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19. Drug Metab Dispos 1996;24:610-4.